Immunicum : Sven Andréasson new Board member

Gothenburg, Sweden, 2013-12-03 14:15 CET (GLOBE NEWSWIRE) — Sven Andréasson has been appointed member of the Board of cancer vaccine company Immunicum AB (publ) in Gothenburg, Sweden. He succeeds Bengt Andersson, who will instead be included in the Company’s Scientific Advisory Board.

Sven Andréasson has many years of experience in both pharmaceutical and biotechnology companies. He was CEO of Active Biotech AB in Lund between 1999 and 2008 and then president of Beta – Cell NV in Brussels. Since March 2012 to November 2013, he was CEO of Isconova AB in Uppsala. After Novavax Inc’s. acquisition, he is Director of Novavax AB. He has held senior positions in the international pharmaceutical industry, including as President and Vice President in, essentially, Swedish, French, Belgian and German companies within the Pharmacia Group. Other directorships: XImmune AB, Lund (Chairman), Erytech SA, Lyon, Cell Astra Inc., San Francisco, Novavax AB, Uppsala and OIL AB, Stockholm, Sweden (Chairman).

– Immunicum is entering a phase of increasing focus on business development and commercial partnerships. Sven Andréasson’s broad experience in the international pharmaceutical industry, including as CEO of Active Biotech and Isconova, will be of great value to the Company as we take the next step in Immunicum’s development, says Immunicum’s Chairman Agneta Edberg. We would like to take this opportunity to thank Bengt Andersson for his great commitment to the Board and look forward to continuing the good collaboration through his new role as a member of our scientific advisory board.

Immunicum’s vaccine cells are comprised of so-called allogeneic dendritic cells, which through a unique processing system are developed into effective immune activating cells. Immunicum’s unique vaccine concept is based on over 30 years of research in the field of transplantation immunology and, by use of a new method, activates the body’s own immune system to attack tumor cells. Immunicum’s shares have been traded since April 22, 2013 on NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company’s Certified Adviser.

Tel: +468-503 000 50.

For further information please contact:

Jamal El-Mosleh, CEO of Immunicum, +4631-772 81 50,

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, and the method of expansion of tumor-specific T-cells (CD70) is based on the Nobel prize awarded discovery of the dendritic cell and its central role in the activation of the specific immune response. Since the raw material consists of allogeneic dendritic cells, Immunicum’s products can be produced in large scale. The vaccines are now undergoing clinical trials in renal cell carcinoma and hepatocellular carcinoma.

Keep reading

Immunicum’s patent application regarding the Company’s core-technology for therapeutic cancer vaccination using allogeneic dendritic cells is being approved in the U.S.